Top broker slaps $175 price target on CSL Limited shares

In early afternoon trade the CSL Limited (ASX: CSL) share price has defied the market and pushed almost 2% higher to $158.60.

This latest gain means that the biotherapeutics company’s shares have now climbed over 25% since this time last year.

The good news for shareholders is that one leading broker doesn’t believe that this is the end of its gains and has tipped its shares to climb even higher from here.

What has the broker said?

According to a note out of UBS, following a change of analyst and valuation methodology, CSL’s shares have been upgraded to a buy rating and had their price target lifted to $175.00 from $155.00.

That price target implies potential upside of over 10% for its shares over the next 12 months.

UBS believes that CSL is capable of growing its earnings at a compound annual growth rate of 16% over the next three years.

Furthermore, its analyst believes that CSL deserves to trade a premium to its historic average due to the strong growth it is exhibiting and favourable conditions in the plasma industry.

UBS isn’t the only company talking up CSL’s prospects at the moment. A note out of Credit Suisse this morning also reveals that its analysts have retained their outperform rating and $173.00 price target on its shares.

Should you invest?

I think CSL is the best healthcare share on the Australian market and feel it is trading at an attractive price for a patient buy and hold investment. In light of this, I would have to agree with both UBS and Credit Suisse that it would be a great investment right now.

Due to its strong long-term growth potential and quality management team, I would class it as my number one pick in the sector just ahead of Cochlear Limited (ASX: COH) and ResMed Inc. (CHESS) (ASX: RMD).

As well as CSL, Cochlear, and ResMed, these top stocks could be great buy and hold investment options.

Top 3 Growth Stocks To Buy In April

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!